SG Americas Securities LLC Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

SG Americas Securities LLC lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 35.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,719 shares of the company’s stock after buying an additional 3,832 shares during the period. SG Americas Securities LLC’s holdings in Kymera Therapeutics were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after purchasing an additional 295 shares during the last quarter. Comerica Bank grew its position in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the period. Keudell Morrison Wealth Management increased its holdings in Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after buying an additional 480 shares during the last quarter. Congress Asset Management Co. MA raised its position in Kymera Therapeutics by 1.2% in the first quarter. Congress Asset Management Co. MA now owns 45,836 shares of the company’s stock worth $1,843,000 after acquiring an additional 533 shares during the period. Finally, Principal Financial Group Inc. raised its position in Kymera Therapeutics by 4.7% in the first quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock worth $486,000 after acquiring an additional 547 shares during the period.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Insiders have sold a total of 41,645 shares of company stock valued at $1,957,552 over the last 90 days. 15.82% of the stock is owned by corporate insiders.

Kymera Therapeutics Stock Up 4.1 %

Shares of Kymera Therapeutics stock opened at $45.02 on Monday. Kymera Therapeutics, Inc. has a twelve month low of $9.60 and a twelve month high of $53.27. The business has a 50-day moving average price of $45.90 and a 200-day moving average price of $39.62. The firm has a market cap of $2.78 billion, a price-to-earnings ratio of -18.60 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.67) EPS. On average, equities analysts expect that Kymera Therapeutics, Inc. will post -2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KYMR has been the subject of several analyst reports. Morgan Stanley upped their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Kymera Therapeutics in a research note on Monday, June 17th. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Monday, September 9th. Finally, Oppenheimer upped their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $49.00.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.